# US 2024/0002845 A1 · Casp8ap2 antagonists for use in the prevention or treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002845 A1
- Document ID: US20240002845A1
- Status: Published application
- Kind: A1
- Application number: 18/031,001
- Filed: 2021-10-07
- Published: 2024-01-04
- Earliest claimed: 2020-10-08
- Assignees: Albert-Ludwigs-Universität Freiburg; Deutsches Krebsforschungszentrum
- Applicants: Albert-Ludwigs-Universitat Freiburg; Deutsches Krebsforschungszentrum
- Inventors: Sven Diederichs; Ksenia Myacheva
- Web page: https://patentgrep.com/patent/US20240002845A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 35/00: Antineoplastic agents
- G01N 33/5011: {for testing antineoplastic activity}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides the use of a CASP8AP2 antagonist in the prevention or treatment of cancer. Preferably, the antagonist reduces the viability of the cancer cells without significantly reducing the viability of normal cells in the subject to be treated. Further, methods of treatment and pharmaceutical compositions suitable in said methods are provided, as well.

## Claims

### Claim 1

A Caspase-8 associated protein-2 (CASP8AP2) antagonist for use in the prevention or treatment of cancer, with the proviso that the CASP8AP2 antagonist is not a peptide comprising the amino acid sequence SMMPDELLTSL (SEQ ID NO: 140) or a peptide comprising the amino acid sequence KLDKNPNQV (SEQ ID NO:141).

### Claim 2 (depends on 1)

The CASP8AP2 antagonist for use according to claim 1, wherein the CASP8AP2 antagonist reduces the viability of the cancer cells.

### Claim 3 (depends on 1)

The CASP8AP2 antagonist for use according to claim 1, wherein the CASP8AP2 antagonist does not significantly reduce the viability of normal cells in the subject receiving the treatment.

### Claim 4 (depends on 1)

The CASP8AP2 antagonist for use according to claim 1, with the proviso that said cancer is not stomach cancer and/or colon cancer and/or rectal cancer.

### Claim 5 (depends on 1)

The CASP8AP2 antagonist for use according to claim 1, wherein the cancer is selected from the group consisting of lung cancer, breast cancer, pancreatic cancer or liver cancer; preferably wherein the cancer is a lung adenocarcinoma, squamous cell lung cancer, ER-/PR-positive breast cancer, triple-negative breast cancer, pancreatic ductal adenocarcinoma or hepatocellular carcinoma; more preferably wherein the cancer is a lung adenocarcinoma.

### Claim 6 (depends on 1)

The CASP8AP2 antagonist for use according to claim 1, wherein the CASP8AP2 antagonist reduces the transcription and/or translation of the CASP8AP2 gene and/or the stability of the CASP8AP2 mRNA or protein.

### Claim 7 (depends on 1)

The CASP8AP2 antagonist for use according to claim 1, wherein the CASP8AP2 antagonist is selected from an antisense oligonucleotide, a small interfering RNA (siRNA), a short hairpin RNA (shRNA), a microRNA (miRNA) or a CRISPR-guide RNA (sgRNA).

### Claim 8 (depends on 7)

The CASP8AP2 antagonist for use according to claim 7, wherein the antisense oligonucleotide is capable of binding to and/or is at least partially complementary to a region of the CASP8AP2 gene or regulatory elements in its close vicinity, preferably the CASP8AP2 gene is human.

### Claim 9 (depends on 7)

The CASP8AP2 antagonist for use according to claim 7, wherein the siRNA is capable of interfering with the gene expression of the CASP8AP2 gene and comprises a first strand of RNA at least partially complementary to 15 nucleotides of the CASP8AP2 gene, and a second strand of RNA of 15 to 30 nucleotides in length, wherein at least 12 nucleotides of the first strand and second strands are complementary to each other and form a siRNA duplex.

### Claim 10 (depends on 7)

The CASP8AP2 antagonist for use according to claim 7, wherein the sgRNA is at least partially complementary to 15 nucleotides of the CASP8AP2 gene and in addition a CRISPR protein lacking endonuclease activity is administered, preferably the CRISPR protein is fused to at least a domain of Kruppel associated box (KRAB) protein.

### Claim 11 (depends on 1)

The CASP8AP2 antagonist for use according to claim 1, wherein the CASP8AP2 antagonist is an antibody specifically binding to CASP8AP2 protein, or a binding fragment thereof, preferably wherein the antibody specifically binding to CASP8AP2 protein at least partially blocks the binding of CASP8AP2 to a caspase selected from caspase-3, caspase-7, caspase-8 or caspase-9, preferably the caspase is caspase-8.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a CASP8AP2 antagonist as defined in claim 1 and a pharmaceutically acceptable excipient.

### Claim 13

A method for identifying a CASP8AP2 antagonist comprising
i) screening a test compound for binding to CASP8AP2 protein;
ii) optionally determining in vitro the caspase-mediated apoptotic activity induced by the test compound identified in step i) in a cancer cell line, wherein the caspase is selected from caspase-3/7, caspase-8 and caspase-9; and
iii) selecting the test compound as a CASP8AP2 antagonist if the test compound binds to CASP8AP2 and optionally increases the apoptotic activity of Caspase-3/7 and/or Caspase-8 and/or Caspase-9 compared to the caspase-mediated apoptotic activity in the absence of the test compound.

### Claim 14

A method for identifying a CASP8AP2 antagonist comprising
i) screening a test compound for binding to CASP8AP2 protein; and
ii) optionally determining in vitro the cell viability of a cancer cell induced by the test compound identified in step i); and
iii) selecting the test compound as a CASP8AP2 antagonist if the test compound binds to CASP8AP2 and optionally reduces the cell viability of the cancer cell compared to the cell viability of the cancer cell in the absence of the test compound.

### Claim 15 (depends on 13)

A method for preparing a pharmaceutical composition comprising a CASP8AP2 antagonist, comprising identifying a CASP8AP2 antagonist by the method of claim 13 and mixing the CASP8AP2 antagonist with at least one pharmaceutically acceptable excipient.
